Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company developing DNAbilize® antisense RNAi nanoparticle technology to produce targeted nucleic acid intravenous drugs, today announced the publication of an analysis stressing upon the unrealized capacity of prexigebersen (BP1001) within the antisense oligonucleotide drug delivery space in the renowned journal, Biomedicines. BPTH stock surged adjacent to the news.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Today, in premarket trading, shares of Bio-Path Holdings Inc. (BPTH) increased 4.57% at $6.18 as of this writing. Bio-Path Holdings Inc.’s stock climbed 6.49% to finish the last trading session at $5.91.In the past 12 months, the BPTH stock has advanced 12.14%, and in the last week, the stock has moved down to -4.21%.
About Bio-Path Holdings, Inc.
The article that was titled “The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery,” emphasizes the problems of an antisense oligonucleotide in the drug delivery space. Some of the challenges include lack of stability in the bloodstream, adequate delivery to specific sites, and cellular uptake. Furthermore, it is explained why prexigebersen, a liposome-incorporated antisense oligodeoxynucleotide targeted against the Grb2 mRNA, has the capability to solve the problems and revolutionize the drug delivery area.
The author of the article includes Maria Gagliardi, Ph.D., Research Scientist at Bio-Path Holdings, and Ana Tari Ashizawa, Ph.D., Senior Vice President of Research, Development, and Clinical Design at Bio-Path Holdings.
Prexigebersen has the capability to overcome problems faced by antisense oligonucleotide drug due to various reasons. Its uncharged surface has been declared non toxic in accordance to pre-clinical and clinical studies. Furthermore, its appropriate biodistribution gives it significant therapeutic modality for cancerous tumors.
Bio-Path’s main product candidate, prexigebersen is in a Phase 2 study for blood cancers. A drug modification of Prexigebersen, is being considered by the Food and Drug Administration to initiate trials for tumors. After which evaluation of BP1002, targeting the Bcl-2 protein, will take place through lymphoma clinical studies.
Conclusion
Potential for prexigebersen to be used significantly in the drug delivery space has peaked investor expectation for the company. Positive data from clinical studies may further enhance BPTH stock price, considering the company’s capability to revolutionize the drug delivery space.
